Geovax Labs (GOVX) Stock
Early stage biotech developing vaccines for infectious diseases. Here's the price, business snapshot, and what's worth knowing about Geovax Labs in August 2026.
Geovax Labs Inc (GOVX) is a clinical-stage biotechnology company developing vaccines using a Modified Vaccinia Ankara virus-like particle (MVA‑VLP) platform. The company has focused on infectious disease targets and aims to elicit robust immune responses through its platform. As a micro‑cap (market capitalisation around $17.2m), Geovax is a speculative, early‑stage investment: clinical data, regulatory decisions and financing events tend to be the primary value drivers. Investors should be aware of common biotech risks — trial setbacks, regulatory hurdles, limited revenues and potential dilution from capital raises — alongside the potential upside if clinical proof‑of‑concept is achieved. This summary is for general educational purposes only and not personalised investment advice. Suitability depends on an individual’s risk tolerance, time horizon and portfolio diversification. Past performance is not an indicator of future results; values can fall as well as rise and returns are not guaranteed.
About This Stock
GEOVAX LABS INC
GOVX
Current Price
$0.63
Potential 12 Month Profit
3,900.00%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
GOVX
Market Cap
$4.73M
Potential 12 Month Profit
3,900.00%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GEOVAX Labs' stock with a target price of $22.75, indicating strong growth potential.
Financial Health
GEOVAX Labs is generating modest revenue and cash flow, indicating stable operations but limited growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Platform Potential
Geovax’s MVA‑VLP platform underpins its vaccine candidates and could offer differentiation if clinical proof emerges, though outcomes are uncertain and long timelines are common.
Clinical Milestones
Trial data and regulatory updates are primary catalysts that can move the stock sharply in either direction; investors should expect binary event risk.
Funding & Liquidity
With a market capitalisation near $17m, Geovax is a micro‑cap with limited liquidity and potential need for further financing, which can dilute existing holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.